Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (3187)	1/4/2002 10:38:56 AM
From: Elmer	Read Replies (1) \| Respond to of 4676

We have had a lot of good news with little corresponding price appreciation. WRT the Amgen deals, I sat next to an AMGN sales rep. on a flight a couple weeks ago and we talked about biotech stocks. I mentioned the deal with ISIP. He said that a lot of these deals are hedges by large companies (like venture capital investments) so that they don't get locked out of certain potential technologies. The deals tend to validate the strength of the patent estate but not necessarily the technology and its future viability. A lot of very smart biotech investors are still skeptical about our company. See Message 16686814 That said, it seems if McCamant is right and they line up a bunch of big pharma deals this year and don't have a product failure (and GNTAs lead drug works), this stock should be a lot higher by year end. Here's to hope. David